Author(s)

Yunhao Lei ¹

Affiliation(s)

¹ College of Medical Imaging, Dalian Medical University, Dalian, Liaoning, 116000, China

Corresponding Author

Yunhao Lei

ABSTRACT

Cancer is a frightening thing in people's eyes. With the change of people's living habits, eating habits, living environment, etc., more and more various diseases haunt us. It is even said that the improvement of the level of technology has enabled us to discover diseases that had not been discovered before. Tumor, there are good and bad points, but also easy to absorb human nutrition, damage people's lives. Therefore, cancer therapy research is related to people's hope of anti-cancer treatment. With the continuous improvement of gene editing technology, the research of CAR-T cell therapy (CT) has made remarkable progress. CAR-T CT, or chimeric antigen receptor T CT, is a revolutionary approach to cancer treatment. It is based on genetic engineering technology, by modifying the patient's own T cells, so that they have the ability to specifically recognize and attack tumor cells. Although chemotherapy and radiotherapy can inhibit the growth of tumors to a certain extent, they are often accompanied by serious side effects such as nausea, vomiting, fatigue, and greater damage to normal cells. In contrast, CAR-T CT has higher targeting and lower side effects. It can achieve the purpose of treating tumors without damaging normal cells. This paper analyzes the role of CAR-T CT in hematologic tumors and solid tumors, so as to provide further evidence for tumor treatment. This paper investigates and analyzes the basic changes of myeloma patients before and after receiving CT and the status of carcinoembryonic antigen, cytokeratin 19 fragment and neuron-specific enolase in lung cancer patients. The blood pressure values of myeloma patients varied from 110 to 130 during the test. Lung cancer patients had smaller fluctuations in neuron-specific enolase, and there was some independence between this tumor marker and the effect of CAR-T CT. The effect of CT on the expansion of B-cell mature antigen in blood is weaker than that in bone marrow. 

KEYWORDS

CAR -T Cell Therapy, Tumor Therapy, Bone Marrow Tumor, Lung Cancer, Cytokine

CITE THIS PAPER

Yunhao Lei, Advances in the Research and Application of CAR-T Cell Therapy in Tumor Therapy. MEDS Basic Medicine (2024) Vol. 2: 86-93. DOI: http://dx.doi.org/10.23977/medbm.2024.020111.

REFERENCES

[1] Cappell K M, Kochenderfer J N. Long-term outcomes following CAR-T cell therapy: what we know so far. Nature Reviews Clinical Oncology, 2023, 20(6): 359-371. 
[2] Johnson P C, Abramson J S. Engineered T cells: CAR-T cell therapy and beyond. Current Oncology Reports, 2022, 24(1): 23-31.
[3] Schett G, Mackensen A, Mougiakakos D. CAR-T-cell therapy in autoimmune diseases. The Lancet, 2023, 402(10416): 2034-2044.
[4] Yang J, Chen Y, et al. Advancing CAR-T cell therapy through the use of multidimensional omics data. Nature Reviews Clinical Oncology, 2023, 20(4): 211-228.
[5] Albelda S M. CAR-T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nature Reviews Clinical Oncology, 2024, 21(1): 47-66.
[6] Mackensen A, Müller F, Mougiakakos D, et al. Anti-CD19 CAR-T cell therapy for refractory systemic lupus erythematosus. Nature medicine, 2022, 28(10): 2124-2132.
[7] Chohan K L, Siegler E L, Kenderian S S. CAR-T cell therapy: the efficacy and toxicity balance. Current hematologic malignancy reports, 2023, 18(2): 9-18.
[8] Amini L, Silbert S K, Maude S L, et al. Preparing for CAR-T cell therapy: patient selection, bridging therapies and lymphodepletion. Nature Reviews Clinical Oncology, 2022, 19(5): 342-355.
[9] Kaczanowska S, Murty T, Alimadadi A, et al. Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. Cancer Cell, 2024, 42(1): 35-51. e8.
[10] Majzner R G, Ramakrishna S, Yeom K W, et al. GD2-CAR-T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature, 2022, 603(7903): 934-941.
[11] Juluri K R, Wu Q V, Voutsinas J, et al. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR-T-cell therapy. Blood Advances, 2022, 6(7): 2055-2068.
[12] Alcantara M, Houillier C, Blonski M, et al. CAR-T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network. Blood, The Journal of the American Society of Hematology, 2022, 139(5): 792-796.
[13] Mullanfiroze K, Lazareva A, Chu J, et al. CD34+-selected stem cell boost can safely improve cytopenias following CAR-T-cell therapy. Blood Advances, 2022, 6(16): 4715-4718.
[14] Fabrizio V A, Boelens J J, Mauguen A, et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR-T-cell therapy. Blood advances, 2022, 6(7): 1961-1968.
[15] Kambhampati S, Sheng Y, Huang C Y, et al. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR-T-cell therapy. Blood advances, 2022, 6(7): 2045-2054.
[16] Faruqi A J, Ligon J A, Borgman P, et al. The impact of race, ethnicity, and obesity on CAR-T-cell therapy outcomes. Blood Advances, 2022, 6(23): 6040-6050.
[17] Huan T, Chen D, Liu G, et al. Activation-induced cell death in CAR-T cell therapy. Human Cell, 2022, 35(2): 441-447.
[18] Young R M, Engel N W, Uslu U, et al. Next-generation CAR-T-cell therapies. Cancer discovery, 2022, 12(7): 1625-1633.
[19] Marcus L, Fashoyin-Aje L A, Donoghue M, et al. FDA approval summary: pembrolizumab for the treatment of tumor mutational burden–high solid tumors. Clinical Cancer Research, 2021, 27(17): 4685-4689.
[20] Tan B, Huang L, Wu Y, et al. Advances and trends of hydrogel therapy platform in localized tumor treatment: A review. Journal of Biomedical Materials Research Part A, 2021, 109(4): 404-425.

Sponsors, Associates, and Links

---

• MEDS Clinical Medicine
  
  
• Journal of Neurobiology and Genetics
  
  
• Medical Imaging and Nuclear Medicine
  
  
• Bacterial Genetics and Ecology
  
  
• Transactions on Cancer
  
  
• Journal of Biophysics and Ecology
  
  
• Journal of Animal Science and Veterinary
  
  
• Academic Journal of Biochemistry and Molecular Biology
  
  
• Transactions on Cell and Developmental Biology
  
  
• Rehabilitation Engineering & Assistive Technology
  
  
• Orthopaedics and Sports Medicine
  
  
• Hematology and Stem Cell
  
  
• Journal of Intelligent Informatics and Biomedical Engineering
  
  
• MEDS Stomatology
  
  
• MEDS Public Health and Preventive Medicine
  
  
• MEDS Chinese Medicine
  
  
• Journal of Enzyme Engineering
  
  
• Advances in Industrial Pharmacy and Pharmaceutical Sciences
  
  
• Bacteriology and Microbiology
  
  
• Advances in Physiology and Pathophysiology
  
  
• Journal of Vision and Ophthalmology
  
  
• Frontiers of Obstetrics and Gynecology
  
  
• Digestive Disease and Diabetes
  
  
• Advances in Immunology and Vaccines
  
  
• Nanomedicine and Drug Delivery
  
  
• Cardiology and Vascular System
  
  
• Pediatrics and Child Health
  
  
• Journal of Reproductive Medicine and Contraception
  
  
• Journal of Respiratory and Lung Disease
  
  
• Journal of Bioinformatics and Biomedicine